Paul Tran

Summary

Affiliation: Harvard School of Public Health
Country: USA

Publications

  1. pmc Early postpartum pharmacokinetics of lopinavir initiated intrapartum in Thai women
    Tim R Cressey
    Harvard School of Public Health, Boston, Massachusetts, USA
    Antimicrob Agents Chemother 53:2189-91. 2009
  2. pmc Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum
    Tim R Cressey
    Program for HIV Prevention and Treatment IRD URI 174, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand
    J Acquir Immune Defic Syndr 59:245-52. 2012
  3. ncbi request reprint Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1
    Tim R Cressey
    Harvard School of Public Health, Boston, MA, USA
    J Acquir Immune Defic Syndr 38:283-8. 2005
  4. ncbi request reprint Low-doses of indinavir boosted with ritonavir in HIV-infected Thai patients: pharmacokinetics, efficacy and tolerability
    Tim R Cressey
    Harvard School of Public Health, Harvard University, Boston, MA, USA
    J Antimicrob Chemother 55:1041-4. 2005
  5. ncbi request reprint Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an update
    Tim R Cressey
    Harvard School of Public Health, Boston, MA, USA
    Infect Genet Evol 7:333-42. 2007
  6. ncbi request reprint Indinavir/ritonavir remains an important component of HAART for the treatment of HIV/AIDS, particularly in resource-limited settings
    Tim R Cressey
    Chiang Mai University, Program for HIV Prevention and Treatment PHPT IRD174, 29 7 8 Samlan Road, Soi 1 Prasing, Muang, Chiang Mai, 50205, Thailand
    Expert Opin Drug Metab Toxicol 3:347-61. 2007
  7. pmc Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy
    Tim R Cressey
    Department of Medical Technology, Chiang Mai University, Thailand
    AIDS 24:2193-200. 2010
  8. pmc Influence of body weight on achieving indinavir concentrations within its therapeutic window in HIV-infected Thai patients receiving indinavir boosted with ritonavir
    Tim R Cressey
    Program for HIV Prevention and Treatment IRD URI 174, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand
    Ther Drug Monit 33:25-31. 2011

Collaborators

  • Gonzague Jourdain
  • Marc Lallemant
  • Mark Mirochnick
  • Nicole Ngo-Giang-Huong
  • Pilaipan Puthavathana
  • Thanyawee Puthanakit
  • Nottasorn Plipat
  • Maureen Shannon
  • Sombat Thanprasertsuk
  • Deborah Hirt
  • Jean Marc Treluyer
  • Saik Urien
  • K Chokephaibulkit
  • L M Frenkel
  • Tim R Cressey
  • Chureeratana Bowonwatanuwong
  • Prapap Yuthavisuthi
  • Sinart Prommas
  • Yardpiron Taworn
  • Prakit Yothipitak
  • Suriyan Tanasri
  • Renoo Wongsrisai
  • Dujrudee Chinwong
  • Kanchana Than-in-at
  • Pra ornsuda Sukrakanchana
  • Pimpinun Punyati
  • Luc Decker
  • Sophie Le Coeur
  • Borwornluck Changlor
  • Suwalai Chalermpantmetagul
  • Kanjana Yoddee
  • Ruethai Wongchai
  • Tiwacha Thimakam
  • Aksorn Lueanyod
  • Elizabeth Smith
  • Ken McIntosh
  • Patcharaporn Krueduangkam
  • Sanupong Chailert
  • Suporn Koetsawang
  • Somrat Matchua
  • Jullapong Achalapong
  • Ubon Chanasit
  • Janjira Thonglo
  • Nusara Krapunpongsakul
  • Nantasak Chotivanich
  • Marina Thitathan
  • Pisut Greetanukroh
  • Kessarin Chaisiri
  • Edmund Capparelli
  • Prattana Leenasirimakul
  • Michel Tod
  • Suparat Kunkeaw
  • Brookie M Best
  • Yanling Huo
  • Pannee Sirivatanapa
  • Chanon Neungton
  • Alice Stek
  • Sirinat Toyang
  • Intira Collins
  • Guttiga Halue
  • Praornsuda Sukrakanchana
  • Den Roumsuk
  • Orapin Khatngam
  • Supawadee Tongsakulrungruang
  • Anchalee Singkaew
  • Suppanut Khannak Jiradsadaporn Khanmali
  • Malee Techapornroong
  • Praneet Pinklow
  • Kantinan Leepaiboon
  • Sunee Hanyutthapong
  • Parinee Suebchart
  • Wanpen Leelaporn
  • Wilai Raiva
  • Jantra Chalasin
  • Tiemjan Keowkarnkah
  • Sompong Wannun
  • Waropart Pongchaisit
  • Benjawan Thomyota
  • Prateung Lianpongsabuddhi
  • Noupporn Jenpoomjai
  • Ampika Kaewbundit
  • Suchada Thongsuwan
  • Raewadee Wanno
  • Prateep Kanjanavikai
  • Panida Pongpunyayuen
  • Boonrak Wiriyachoke
  • Thamon Wijitwong
  • Boonyavee Ratchanee
  • Arthit Cheawchan
  • Chisakan Thanadechworasate

Detail Information

Publications8

  1. pmc Early postpartum pharmacokinetics of lopinavir initiated intrapartum in Thai women
    Tim R Cressey
    Harvard School of Public Health, Boston, Massachusetts, USA
    Antimicrob Agents Chemother 53:2189-91. 2009
    ..2 (8.0 to 17.5) microg/ml, and 4.6 (1.7 to 12.5) microg/ml, respectively, at 41 (12 to 74) h after delivery. All of the women attained adequate LPV levels through 30 days postpartum. No serious adverse events were reported...
  2. pmc Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum
    Tim R Cressey
    Program for HIV Prevention and Treatment IRD URI 174, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand
    J Acquir Immune Defic Syndr 59:245-52. 2012
    ..The impact of pregnancy on efavirenz (EFV) pharmacokinetics is unknown...
  3. ncbi request reprint Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1
    Tim R Cressey
    Harvard School of Public Health, Boston, MA, USA
    J Acquir Immune Defic Syndr 38:283-8. 2005
    ..To determine nevirapine (NVP) plasma levels during the postpartum period after a single intrapartum NVP dose for the prevention of mother-to-child transmission...
  4. ncbi request reprint Low-doses of indinavir boosted with ritonavir in HIV-infected Thai patients: pharmacokinetics, efficacy and tolerability
    Tim R Cressey
    Harvard School of Public Health, Harvard University, Boston, MA, USA
    J Antimicrob Chemother 55:1041-4. 2005
    ..To assess the steady-state pharmacokinetics of two reduced doses of indinavir boosted with ritonavir (indinavir/ritonavir) in HIV-infected Thai patients...
  5. ncbi request reprint Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an update
    Tim R Cressey
    Harvard School of Public Health, Boston, MA, USA
    Infect Genet Evol 7:333-42. 2007
    ....
  6. ncbi request reprint Indinavir/ritonavir remains an important component of HAART for the treatment of HIV/AIDS, particularly in resource-limited settings
    Tim R Cressey
    Chiang Mai University, Program for HIV Prevention and Treatment PHPT IRD174, 29 7 8 Samlan Road, Soi 1 Prasing, Muang, Chiang Mai, 50205, Thailand
    Expert Opin Drug Metab Toxicol 3:347-61. 2007
    ..Similar low dosing levels in children have also proven successful, but data in pregnant women remains limited. Due to its low cost and proven efficacy indinavir remains a key component of HIV/AIDS treatment in resource-limited settings...
  7. pmc Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy
    Tim R Cressey
    Department of Medical Technology, Chiang Mai University, Thailand
    AIDS 24:2193-200. 2010
    ....
  8. pmc Influence of body weight on achieving indinavir concentrations within its therapeutic window in HIV-infected Thai patients receiving indinavir boosted with ritonavir
    Tim R Cressey
    Program for HIV Prevention and Treatment IRD URI 174, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand
    Ther Drug Monit 33:25-31. 2011
    ..The risk of toxic drug concentrations increases rapidly with IDV/r dose of 600/100 mg for patients less than 50 kg and therapeutic drug monitoring of IDV concentrations would help to reduce the risk of IDV-induced nephrotoxicity...